Based on the therapeutic benefit of the anti-CD20 antibody rituximab to deplete mature B cells in AID, strategies were developed to discover selective BTK inhibitors (BTKi) for the treatment of rheumatoid arthritis (RA; Pan et al., 2007). This evidence concerns the gene BTK and rheumatoid arthritis.